C. Kunz

发表

APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis

M. Fontenay, A. Rouquette, O. Kosmider, 2016, Oncotarget.

Wolber Discovery of novel α-amylase inhibitors using structure-based drug design P 2

W. Huisinga, G., U. Holzgrabe, 2014 .

Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients.

K. Debatin, M. Seiz, J. Tuettenberg, 2012, International immunopharmacology.

APG101_CD_002: A phase II, randomized, open-label, multicenter study of weekly APG101 plus reirradiation versus reirradiation in the treatment of patients with recurrent glioblastoma.

J. Pichler, R. Stupp, J. Debus, 2012 .

Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma

A. von Deimling, U. Haberkorn, J. Debus, 2018, Molecular Cancer Research.

fundiInhibition of CD95/CD95L Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma

U. Haberkorn, A. Abdollahi, A. Deimling, 2018 .

A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma

J. Pichler, I. Harting, A. von Deimling, 2014, Clinical Cancer Research.

Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile

T. Luft, D. Nowak, T. Boch, 2020, Cancers.

Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS.

C. Schumann, T. Luft, D. Nowak, 2017, Leukemia research.

Intracellular localization of 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidino-pteridine in membrane structures impeding the inhibition of cytosolic cyclic AMP-specific phosphodiesterase.

D. Marko, G. Eisenbrand, K. Merz, 2002, Biochemical pharmacology.

Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients

T. Lehr, N. Hanke, H. Fricke, 2019, Pharmaceutics.

Cancer Therapy : Clinical A Phase II , Randomized , Study of Weekly APG 101 þ Reirradiation versus Reirradiation in Progressive Glioblastoma

J. Pichler, K. Junge, W. Wick, 2014 .

A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma

J. Pichler, I. Harting, A. von Deimling, 2014, Clinical Cancer Research.

APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis

M. Fontenay, O. Kosmider, N. Chapuis, 2016, Oncotarget.